U.S., Aug. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07770217) titled 'A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504' on July 20.

Brief Summary: This is a single-center, open-label, fixed-sequence, self-controlled Phase I clinical study with a planned enrollment of approximately 18 healthy participants.

Study Start Date: Aug. 02

Study Type: INTERVENTIONAL

Condition: Healthy Participants

Intervention: DRUG: HS-10504

Participants will receive a single oral dose of 400 mg HS-10504 tablets on study days D1 and D17, respectively

DRUG: Rifampin

articipants will receive Rifampin capsules 600 mg orally once daily on an empty stomach from Day 10 to Day 24 for 15 consecutive days

Re...